Literature DB >> 35528129

Cardiac tamponade as the initial presentation of autoimmune polyglandular syndrome Type 2: a case report.

Laura R Glick1, Daniel Z Hodson1, Shreyak Sharma1, Stella Savarimuthu2.   

Abstract

Background: Cardiac tamponade is a rare but serious manifestation of autoimmune polyglandular syndrome Type 2 (APS 2). Patients often present with symptoms of thyroid dysfunction and adrenal insufficiency, but the insidious onset of the disease may lead to delayed diagnosis, which can progress rapidly to haemodynamic instability requiring urgent intervention. Case summary: A 39-year-old previously healthy male was admitted with cardiac tamponade complicated by cardiac arrest requiring emergent pericardiocentesis. An extensive work up revealed primary adrenal insufficiency and Hashimoto's thyroiditis. His positive autoantibodies to thyroid peroxidase and 21-hydroxylase combined with rapid improvement with initiation of corticosteroids and levothyroxine confirmed a diagnosis of APS 2. Discussion: Although this disease is often difficult to diagnose given its vague symptoms, it should be considered in the differential diagnosis for young patients presenting with pericardial effusion or cardiac tamponade of unknown origin. Early diagnosis and management are critical and often result in rapid improvement after appropriate treatment.
© The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Cardiology.

Entities:  

Keywords:  Adrenal insufficiency; Autoimmune polyglandular syndrome Type 2; Cardiac tamponade; Case report

Year:  2022        PMID: 35528129      PMCID: PMC9071554          DOI: 10.1093/ehjcr/ytac145

Source DB:  PubMed          Journal:  Eur Heart J Case Rep        ISSN: 2514-2119


Cardiac tamponade can be a rare but deadly manifestation of primary adrenal insufficiency disease and autoimmune polyglandular syndrome Type 2. Even in patients without known risk factors, haemodynamic instability in the setting of an acute pericardial effusion should be considered tamponade until proven otherwise. Early, definitive treatment often allows for quick recovery in these patients arrived. Patients with rare diseases benefit from a broad differential and a multidisciplinary team approach to diagnosis and management.

Introduction

Autoimmune polyglandular syndrome Type 2 (APS 2), also called autoimmune polyendocrine syndrome or polyglandular autoimmune syndrome Type 2, describes the co-occurrence of autoimmune adrenal insufficiency with autoimmune thyroid disease and/or Type 1 diabetes mellitus. It is a rare syndrome, with an incidence estimated as 1.4–4.5 per 100 000. Patients often present with symptoms of thyroid dysfunction and non-specific symptoms of adrenal insufficiency. However, the disease occasionally presents with life-threatening cardiac tamponade. The below case describes a young, otherwise healthy patient who presented with acute onset cardiac tamponade, ultimately leading to a diagnosis of APS 2.

Case presentation

A 39-year-old male with no significant past medical history presented to the emergency department with 3 months of unintentional weight loss and 2 days of worsening epigastric pain. On initial presentation to the outside hospital, he was afebrile, tachycardic to 108, hypotensive to 80/39, tachypnoeic to 24 with oxygen saturation 100% on room air. His physical examination on arrival was notable only for diffuse hyperpigmentation. His initial work up revealed a slight leucocytosis to 10.3 × 109/L (reference range: 4.0–10.0 × 109/L), sodium of 128 mmol/L (reference range: 136–145 mmol/L), C-reactive protein elevated at 3.1 mg/dL (reference range <0.30 mg/dL), B-type natriuretic peptide pro (proBNP) of 1,428.0 pg/mL (reference range <125 pg/mL) and a negative troponin. He was resuscitated with 4 L of normal saline without improvement in his blood pressure. His initial electrocardiogram (ECG) showed sinus tachycardia and low voltage without electrical alternans (). His chest X-ray showed increased bilateral interstitial markings without any focal infiltrates. Computed Tomography Angiography (CTA) was negative for pulmonary embolus but revealed a trace pericardial effusion. An initial transthoracic echocardiogram (TTE) before intubation demonstrated a mild-to-moderate pericardial effusion without evidence of right atrial or ventricular collapse (), mildly increased right atrial pressure as evidenced by IVC diameter measuring <2.1 cm and collapsing <50% with a sniff. There was also increased variation of mitral inflow velocities on which the official report did not comment (). Left ventricular ejection fraction (LVEF) was estimated by visual assessment to be preserved at 55–60%. The patient became progressively altered requiring intubation for airway protection. Despite these interventions, he was acidotic to an arterial pH of 7.04 and had a pulseless electrical activity arrest for 6 min requiring Advanced Cardiovascular Life Support, after which return of spontaneous circulation was achieved. He subsequently required three vasopressors and was airlifted to the medical intensive care unit at a tertiary care centre for further management. Electrocardiograms. The patient initially presented with tachycardia and low voltage (A), the latter of which did not resolve immediately after pericardiocentesis (B). Transthoracic echocardiograms. Initial echo at the outside hospital did not reveal right ventricular diastolic collapse (A), but did show increased variability of mitral inflow velocities (B). Repeat echo at our tertiary hospital showed right ventricular diastolic collapse (C and D), while variations in inflow velocities partially reflected the patient’s intubated status (E and F). In the cath laboratory (G), ∼200 mL was removed, which essentially resolved the effusion (H). The patient arrived to our unit on norepinephrine 3 mcg/kg/min, phenylephrine 9 mcg/kg/min, and vasopressin 0.03 mcg/kg/min. Repeat TTE showed evidence of tamponade physiology including a large circumferential pericardial effusion measuring 2.6 cm and diastolic collapse of the right ventricular free wall ( and ). Respiratory variation in inflow velocities is more difficult to interpret in an intubated patient ( and ). A left-sided pleural effusion was also noted on TTE, whereas a right-sided pleural effusion was noted on transesophageal echocardiography (TEE). His TEE also showed mild global hypokinesis with LVEF decreased to 40–45%. The patient underwent emergent pericardiocentesis with the removal of 200 mL of serosanguinous fluid ( and ) leading to improvement in his haemodynamics. The patient arrived at the cath laboratory and pressors were titrated during the procedure to support perfusion. About 1 h after completion of the pericardiocentesis, the patient had been weaned off phenylephrine but remained on norepinephrine and vasopressin. His repeat ECG () continued to show low voltage. Given the unclear aetiology of his tamponade, a broad infectious and autoimmune work up was sent (). His thyroid-stimulating hormone (TSH) was elevated to 30 μIU/mL (reference range: 0.27–0.42 μIU/mL) with a T3 of 67.3 ng/dL (reference range: 72–153 ng/dL) and a free T4 of 0.34 ng/dL (reference range: 0.8–1.7 ng/dL). His random cortisol was <0.05 μg/dL and his cosyntropin stimulation test revealed an elevated adrenocorticotropic hormone (ACTH) and undetectable cortisol, leading to a diagnosis of primary adrenal insufficiency. Computed tomography of the abdomen showed slightly atrophic adrenal glands bilaterally. Further autoimmune work up was significant for an elevated antinuclear antibody (1:80, dense fine speckled), as well as an elevated thyroid peroxidase antibody and 21-hydroxylase antibody level. High-dose corticosteroids and levothyroxine were initiated on hospital Day 3, and the patient showed marked improvement; he was extubated and weaned off all vasopressors by hospital Day 4. The combination of autoimmune adrenal insufficiency and autoimmune thyroid disease confirmed a diagnosis of APS 2. Presenting laboratories and work up TSH, thyroid-stimulating hormone; ACTH, adrenocorticotropic hormone; Ab, antibody; Ag, antigen; IGF-1, insulin-like growth factor; ANA, antinuclear antibody; ANCA, antineutrophil cytoplasmic antibody; RF, rheumatoid factor; SS, Sjögren’s syndrome; IL-6, interleukin-6 The patient was admitted to the hospital for 12 days (6 of which were in the intensive care unit). Repeat TTE on hospital Day 2 and Day 4 demonstrated bilateral pleural effusions. Following the pericardiocentesis, electrocardiogram continued to show low voltages. The patient’s LVEF recovered to 55–60% by hospital Day 7. He was discharged home on hydrocortisone 20 mg in the morning, hydrocortisone 10 mg at night and levothyroxine 125 mcg daily with close follow-up. Twelve weeks later, he presented to the hospital with pleuritic chest pain, upper abdominal pain, and nausea and was readmitted briefly with pericarditis. CTA showed small pericardial effusion with pericardial thickening and trace bilateral pleural effusions noted, whereas TTE showed trivial pericardial effusion without evidence of haemodynamic compromise. The patient was treated with intravenous fluids, stress dose hydrocortisone, ibuprofen, and colchicine before being discharged home with outpatient follow-up.

Discussion

Autoimmune polyglandular syndrome Type 2 is a rare immunoendocrinopathy affecting the adrenal glands and the endocrine pancreas and/or the thyroid. Although APS 2 can affect individuals across the lifespan, onset occurs most commonly between the age of 30 and 40 with a female predominance (female:male ratio ranging from 1.8 to 4.0).[1-5] Specific HLA haplotypes have been found to be associated with autoimmune adrenal insufficiency in APS 2.[1,2,6] However, the pathogenesis remains poorly elucidated. One theory involves the development of autoantibodies against antigens from the same embryologic germ layer, but this would not explain the autoimmune disease in organs from different germ layers or why endocrine organs seem preferentially affected in these syndromes while other organs from within the same germ layer would be unaffected.[1] Loss of regulatory T-cell function could help explain autoimmunity against multiple targets and organ systems.[6] It also remains unclear if the loss of tolerance to multiple antigens occurs simultaneously or sequentially.[1] Patients often present with symptoms of thyroid dysfunction (either hypothyroid or hyperthyroid) and non-specific symptoms of adrenal insufficiency (including fatigue, weight loss, decreased appetite, and abdominal pain). In addition, patients may present with other autoimmune conditions including vitiligo, hypogonatropic hypogonadism, autoimmune hepatitis, alopecia, pernicious anaemia, myasthenia gravis, or Sjögren syndrome.[1-3,7] Owing to cortisol and aldosterone deficiencies, general laboratory findings in patients with primary adrenal insufficiency include hyponatraemia, hyperkalaemia, Type IV renal tubular metabolic acidosis, hypoglycaemia or decreasing insulin requirements, hypercalcaemia, mild normocytic anaemia, lymphocytosis, and mild eosinophilia.[7,8] Diagnosis involves serologies and organ function tests. Autoantibodies against the adrenal glands (21 hydroxylase antibodies, adrenal cortex antibodies), thyroid (thyroid peroxidase antibodies, thyroglobulin anitbodies), and pancreas (glutamic acid decarboxylase autoantibodies, insulin autoantibodies, islet cell cytoplasmic autoantibodies, tyrosine phosphatase-like autoantibodies, and insulinoma-associated 2 autoantibodies) are often present. There are no specific imaging findings in APS 2; the adrenal glands often appear normal but may become atrophied later in the course.[1] Pericardial effusions have been reported in primary adrenal insufficiency, and in recent years, there have been multiple case reports of patients with APS 2 initially presenting with pericardial effusion and/or cardiac tamponade ().[9-15] The pathogenesis of the effusion in APS 2 may result from autoimmune inflammation of the pericardium with resulting inflammatory reaction and fluid accumulation. Characteristics of previously reported cases of cardiac tamponade in Autoimmune polyglandular syndrome, type II TSH: Thyroid stimulating hormone; WBC: White blood cells; PMN: Polymorphonuclear neutrophils; LDH: lactate dehydrogenase; JVD: jugular venous distension; NSR: normal sinus rhythm; RAP: right atrial pressure; PCWP: pulmonary capillary wedge pressure; RVDP: right ventricular diastolic pressure; IVC: inferior vena cava; ENA: extractable nuclear antigen; SLE: Systemic Lupus erythematosus Tamponade physiology may develop more easily in the setting of primary adrenal insufficiency due to several factors. First, aldosterone deficiency results in mild intravascular volume depletion, which decreases right-sided filling and allows right atrial and ventricular collapse.[9,11,13] Second, baseline cortisol deficiency results in decreased vascular tone, and therefore propensity towards hypotension.[10] Finally, these patients lack a stress response and are therefore at higher risk for haemodynamic instability and shock in the acute setting.[10,14] In our patient, the aetiology of cardiac arrest was likely multifactorial, including distributive shock secondary to adrenal crisis, worsening severe acidosis, and tamponade physiology. The persistence of refractory shock at our tertiary care hospital reflected continued adrenal crisis and worsening tamponade physiology, as removal of the pericardial fluid resulted in immediate, although partial, improvement in haemodynamics. Nine reported cases of tamponade in APS 2 are summarized in . Several themes emerge from these case reports, and the current case reflects each of these themes. First, patients were relatively young (aged 21–58 years old) and healthy, aside of pre-existing autoimmune disease. Although there is a female predominance for APS 2, two-thirds of the published tamponade cases occurred in males. In addition, these patients presented with non-specific symptoms, but physical examination revealed signs of tamponade physiology. Interestingly, the amount of fluid responsible for haemodynamic instability in these patients may be relatively small. From the six cases in which the volume of pericardial removed was reported, two had <200 mL removed. Finally, pericardial effusion often recurs, necessitating frequent adjustment of hormone replacement and often pericardial window; among the nine cases, four had recurrent tamponade, two had recurrent pericarditis, and one had recurrent pleural effusions. In our case, the patient was a young healthy male who presented with non-specific symptoms, atrophic adrenal glands, accumulation of 200 mL of pericardial fluid causing haemodynamic instability, and has had at least one episode of recurrent pericarditis following initial diagnosis.

Conclusion

Cardiac tamponade is a rare but serious manifestation of APS 2. Although this disease is often difficult to diagnose given its vague symptoms, it should be considered in the differential diagnosis, especially in young patients presenting with cardiac tamponade of unknown origin. Early diagnosis and management are critical and often result in rapid improvement after the initiation of corticosteroids.

Lead author biography

Laura Glick, MD, is a currently a third-year resident in internal medicine at Yale New Haven Hospital. She received her Bachelor’s degree from Tufts University and her MD degree from the University of Chicago Pritzker School of Medicine. She has published more than 30 peer-reviewed articles, and she has presented her research nationally and internationally. In addition, she was featured in the “Diagnosis” column of the the New York Times and on the Clinical Problem Solvers Podcast for her work with this case. Click here for additional data file.
Arrival to the ED (Day 0): A 39-year-old male with no past medical history presented with epigastric pain. Vital signs were significant for tachycardia to 108, hypotensive to 80/39, tachypnoeic to 24 with oxygen saturation 100%, prompting aggressive fluid resuscitation
1 h after arrival (Day 0): laboratory findings largely unremarkable but still hypotensive. Echocardiogram with mild pericardial effusion with no evidence of right atrium or ventricle compromise
3 h after arrival (Day 0): Developed progressive hypoxaemia requiring intubation
4 h after arrival (Day 0): Pulseless electrical activity cardiac arrest for 6 min with return of spontaneous circulation (ROSC) following Advanced Cardiovascular Life Support (ACLS)
5 h after arrival (Day 0): Transferred via helicopter to medical intensive care unit at a tertiary care centre on norepinephrine 3 mcg/kg/min, phenylephrine 9 mcg/kg/min, and vasopressin 0.03 mcg/kg/min
7 h after arrival (Day 0): Repeat echocardiogram with large pericardial effusion with reduced ventricular filling. Underwent emergent pericardiocentesis but still required vasopressors
Day 3: Found to have elevated thyroid-stimulating hormone (TSH) and low free thyroxine (T4), random cortisol of <0.05 and his cosyntropin stimulation test revealed an elevated adrenocorticotropic hormone (ACTH) and undetectable cortisol. Started on high-dose corticosteroids and levothyroxine with improvement in haemodynamics
Day 4: Extubated and weaned off of vasopressors
Day 6: Transferred out of the intensive care unit
Day 12: Discharged home
Three months after discharge: Readmitted to the hospital with mild pericarditis (without tamponade), discharged after 2 days on colchicine and ibuprofen.
Table 1

Presenting laboratories and work up

TestResultReference range
Chemistry
TSH300.27–0.42 μIU/mL
T3, total67.372–153 ng/dL
Free T40.3472–153 ng/dL
ACTH5607.2–63.3 pg/mL
Cortisol<0.05Variable, 0.2–18 μg/dL
Immunology
Thyroid peroxidase Ab182<34 IU/mL
21-hydroxylase AbPositiveNegative
Adrenal total auto AbNegativeNegative
Glutamic acid decarboxylase0.0<0.02 nmol/L
IGF-13353–331 ng/mL
ANA1:80 (dense fine speckled)<1:80
ANCA panel (c-ANCA, p-ANCA)NegativeNegative
Myeloperoxidase Ab2.8<3.5 EliA U/mL
Proteinase 3 Ab<0.7<2.0 EliA U/mL
RF<10<14 IU/mL
dsDNA Ab, IgG0.8<0.10 IU/mL
SS-A0.6<7 EliA U/mL
SS-B0.6<7 EliA U/mL
Smith Ab2.5<7 EliA U/mL
Scleroderma (Scl-70)0.8<7 EliA U/mL
Jo-1 Ab0.3<7 EliA U/mL
IL-6619<7.0 pg/mL
Microbiology
BabesiaNot detected
Treponema pallidum, serumNot detected
Respiratory viral panelNot detected
CytomegalovirusNot detected
Enterovirus and parechovirusNot detected
Lyme antibodiesNot detected
Anaplasma, DNA PCRNot detected
Epstein–Barr VirusNot detected
Cryptococcal AgNegative
Fungitell (1-3)-B-D-glucanNegative
Aspergillus galactomannan antigenNegative
Histoplasma Ag, urineNegative
Legionella and S. PneumoNegative

TSH, thyroid-stimulating hormone; ACTH, adrenocorticotropic hormone; Ab, antibody; Ag, antigen; IGF-1, insulin-like growth factor; ANA, antinuclear antibody; ANCA, antineutrophil cytoplasmic antibody; RF, rheumatoid factor; SS, Sjögren’s syndrome; IL-6, interleukin-6

Table 2:

Characteristics of previously reported cases of cardiac tamponade in Autoimmune polyglandular syndrome, type II

Alkaabi et al. 2008[9]Alkaabi et al. 2008[9]Alkaabi et al. 2008[9]Palmer et al. 2014[10]Khalid et al. 2015[11]McNamara et al. 2017[12]Vryonidou et al. 2017[13]Bacal et al. 2018[14]Marinho et al. 2020[15]
Age/Sex 34 y/o F58 y/o M35 y/o M54 y/o M48 y/o F29 y/o M40 y/o F21 y/o M32 y/o M
History of present illness Breathlessness, central chest pain, and long-standing lethargy with weight lossLong-standing lethargy, weight loss, nausea, and excessive tiredness on minimal exertionLong-standing breathlessness, Unusual gum hyperpigmentation noted during a dental visitFour days of worsening weakness, subjective fevers, nausea, and malaise leading to decreased oral intake, Two days of non-radiating substernal, dull, pleuritic chest painFatigue, malaise, sudden onset of pleuritic left-sided chest pressure, and associated shortness of breath.Positional chest painAdmitted to ICU for rapid onset dyspnea and orthopnea in setting of progression weakness, 10kg weight loss, and amenorrhea during last year with intermittent fever in previous two monthsFlu-like symptoms 1-2 days, chest painThree days of retrosternal chest pain and low-grade fevers
Vitals and Exam Afebrile, severely hypotensive, hyperpigmented, tachycardiac, distant heart soundsHyperpigmented and had pulsus paradoxusAdmitted to medical ICU with hypotension and hypoxiaStriking hyperpigmentationSomnolent SBP 60s following 4L NSJVD to angle of the jaw Distant heart sounds Diminished peripheral pulsesBP 90-100/40-60 HR 110-120 Decreased breath sounds, dullness to percussion, decreased tactile fremitus JVP 12cmBP 70/40 HR 130 JVD to the angle of the mandible Soft heart sounds Friction rubFebrile Tachycardic Hypotensive Slight hyperpigmentationBP 108/64 (on pressors) HR 121Friction rub
Past medical history Hashimoto thyroiditis on levothyroxineNo reported significant past medical historyAutoimmune thyroiditis on levothyroxineLongstanding primary adrenal insufficiency (no longer on fludrocortisone but prednisone) and primary hypothyroidism on levothyroxineKnown APS II with Addison's disease on predisone and fludrocortisone and autoimmune primary hypothyroidism (no comment on levothyroxine dose)HypothyroidismHashimoto thyroiditis on levothyroxineRaynuad'sChildhood asthma Nonallergic rhinitis Idiopathic episcleritis Recent admission for tonsillitis c/b septic shock
General laboratory studies Hyponatremia; Hyperkalemia; AcidosisTSH: 8 mIU/L ACTH: 355 pg/mL Cortisol: undetectable250-mcg cosyntropin stimulation test confirmed adrenal insufficiencyTSH: 25 mIU/L ACTH: 261 pg/mL Cortisol: undetectable250-mcg cosyntropin stimulation test confirmed adrenal insufficiencyNa 132 mEq/L K 4.9 mEq/L Anemia Albumin 1.8 TSH: 12 mIU/L ACTH: 137 pg/mL Cortisol: 1.6 µg/dL before and 1.7 µg/dL 1 hour after 250-mcg cosyntropin stimulation testingNa 131 mEq/L HCO3 17 mmom/L Cr 1.7 mg/dL INR 1.2 ALT 56 u/l AST 61 u/L Total bilirubin 2 mg/dL CRP: 87.5 mg/LTSH wnl Cortisol: undetectableWBC 16,3000 /uL with 85% PMN Na 131 Phos 1.7 mg/dL Mg 1.4 mg/dL Ionized Ca 1.04 mg/dLMorning and random cortisol: undetectableNa 131 mEq/L Hb 11.3 mg/dL CRP 26.4 mg/D C4 9ng/dLAM cortisol 5 µg/dL, ACTH: >1400pg/mLTroponin 2.19 ng/mL TSH 17.9 uL/mL T4: 1.0 Cortisol 0.5ug/dL (midday on pressors, intubated, balloon pump) Coxsackie B type 5 antibodies: 1:160Cortisol: undetectable ACTH: 172 pg/mL
Auto-antibodies Thyroperoxidase “Adrenal”ThyroperoxidaseThyroperoxidase Transglutaminase EndomysialNone reportedNone reportedThyroid peroxidase 21-hydroxylase Glutamic acid decarboxylaseParietal cellThyroid peroxidase Thyroglobulin Glutamic acid decarboxylase 21-hydroxylaseAnti-intrinsic factor Hypogonadism
Electrocardiogram Not reportedNote reportedNot reportedNSR with diffuse ST-segment elevation and PR depressionNSR with low volageDiffuse PR depressionsNone reportedNone reportedSinus tachycardia with widespread STE and PR depression
Echocardiography Large pericardial effusionNotable pericardial fluid and cardiac tamponadeCardiac tamponade(Bilateral pleural effusions on lung ultrasound)Moderately sized loculated pericardial effusion with right ventricular collapse and phasic respiratory hyperdynamic motion of the interventricular septumModerate-sized pericardial effusion, and impaired diastolic filling of the right atrium and right ventricleLow-volume, circumferential pericardial effusion, with diastolic right atrial and right ventricular collapse, and >25% respiratory flow variation across the mitral valve septal to lateral E’ ratio >1.0 and elevated absolute septal E’ velocity of 8.7 cm/sSignificant pericardial effusion(Pleural effusions on lung ultrasound)RV diastolic flattening, significant respiratory variation of mitral and tricuspid inflow, diastolic septal bounce, and plethora of the IVCMild, circumferential pericardial effusion; abnormal rapid motion of interventricular septum (notching in early diastole), lateral e’ velocity lower than the medial e’ velocity, exacerbated respiratory variance of mitral and plethoric IVC, expiratory reversal of diastolic wave
Pericardiocentesis and Cardiac Catheterization 190 mL yellow and cloudy fluid WBC 1500 with 89% PMN LDH: 1748 U/LBacterial, acid-fast, and fungal negativeVolume not reported Fluid: Yellow and +Cloudy WBC 10, 200 with 93% PMN LDH: 295 U/L Bacterial, acid-fast, and fungal negativeVolume not reported Pericardial fluid: Yellow and cloudy WBC 12 438 with 94% PMN LDH: 540 U/L Bacterial, acid-fast, and fungal negative250mL straw colored fluid Mean RAP 14 mmHg Mean PCWP 14mmHg Arterial SBP 40-70mmHg300 mL of thin yellow pericardial fluid by subxiphoid pericardial window Pericardial fluid cultures negative150 mL straw-colored fluid Negative cultures WBC 29,375/mL with 81% PMN RAP and RVDP 25mmHg PCWP 26mmHgVolume not reported Cultures negative400mL amber fluid drained before referral to author's reference hospital350mL serous fluid positive for Streptococcus mitis
Recurrence 7 documented attacks of pericarditis over 28 months1 episode left-sided pleuritis and 5 episodes of pericarditis2 episodes pleural effusions (1 unilateral, 1 bilateral)Similar presentation requiring repeat pericardiocentesis of 140mL blood tinged fluidNone reportedPatient had presented with idiopathic pericarditis with tamponade requiring pericardiocentesis 3 months earlierENA autoantibodies positive on repeat analysis and malar rash, arthritis, polyserositis present so diagnosis of SLE also madeEpisode of recurrent pericarditis with mild to moderate effusion that grew to large effusion within 24 as patient became hypotensive and tachycardic. Managed with pericardial windowEpisode of recurrent pericarditis and tamponade managed with pericardiocentesis and pleuro-pericardial window

TSH: Thyroid stimulating hormone; WBC: White blood cells; PMN: Polymorphonuclear neutrophils; LDH: lactate dehydrogenase; JVD: jugular venous distension; NSR: normal sinus rhythm; RAP: right atrial pressure; PCWP: pulmonary capillary wedge pressure; RVDP: right ventricular diastolic pressure; IVC: inferior vena cava; ENA: extractable nuclear antigen; SLE: Systemic Lupus erythematosus

  14 in total

Review 1.  Autoimmune polyglandular syndrome. II: Clinical syndrome and treatment.

Authors:  Desmond A Schatz; William E Winter
Journal:  Endocrinol Metab Clin North Am       Date:  2002-06       Impact factor: 4.741

Review 2.  Adrenal insufficiency.

Authors:  W Oelkers
Journal:  N Engl J Med       Date:  1996-10-17       Impact factor: 91.245

3.  Effusive Constrictive Pericarditis in Autoimmune Polyglandular Syndrome Type II.

Authors:  David McNamara; Haru Yamamoto; Venetia Sarode; Vlad G Zaha
Journal:  Am J Med       Date:  2017-02-20       Impact factor: 4.965

Review 4.  Autoimmune polyglandular syndrome, type II.

Authors:  Barbara A Majeroni; Parag Patel
Journal:  Am Fam Physician       Date:  2007-03-01       Impact factor: 3.292

5.  Case Report: Autoimmune Polyglandular Syndrome Type 2 Complicated by Acute Adrenal Crisis and Pericardial Tamponade in the Setting of Normal Thyroid Function.

Authors:  Nauman Khalid; Lovely Chhabra; Sarah Aftab Ahmad; Affan Umer; David H Spodick
Journal:  Methodist Debakey Cardiovasc J       Date:  2015 Oct-Dec

Review 6.  Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction.

Authors:  Corrado Betterle; Chiara Dal Pra; Franco Mantero; Renato Zanchetta
Journal:  Endocr Rev       Date:  2002-06       Impact factor: 19.871

Review 7.  Two types of autoimmune Addison's disease associated with different polyglandular autoimmune (PGA) syndromes.

Authors:  M Neufeld; N K Maclaren; R M Blizzard
Journal:  Medicine (Baltimore)       Date:  1981-09       Impact factor: 1.889

Review 8.  Polyglandular autoimmune syndromes.

Authors:  George J Kahaly
Journal:  Eur J Endocrinol       Date:  2009-05-01       Impact factor: 6.664

9.  Pericarditis with cardiac tamponade and addisonian crisis as the presenting features of autoimmune polyglandular syndrome type II: a case series.

Authors:  Juma M Alkaabi; Constance L Chik; Richard Z Lewanczuk
Journal:  Endocr Pract       Date:  2008 May-Jun       Impact factor: 3.443

10.  Incessant Pericarditis With Recurrent Cardiac Tamponade as the Manifestation of Autoimmune Polyglandular Syndrome Type II.

Authors:  Ana V Marinho; Rui Baptista; Luís Cardoso; Patrícia M Alves; Sílvia Monteiro; Francisco Gonçalves; Lino Gonçalves
Journal:  JACC Case Rep       Date:  2020-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.